Oncology News | pharmaphorum

News

Aviva backs £1bn cancer hub in London

A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

Rare womb cancer is a women’s health success story

Imagine being told just after giving birth to a new baby that you have cancer.

News

J&J doublet beats Tagrisso in first-line lung cancer

AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in

News

Novartis eyes first-line use of Lutathera after trial win

Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben

News

Seagen hails ‘practice-changing’ trial in bladder cancer

A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has significantly improved survival compared to chemotherapy in previously untreated patients with advanc

Aviva backs £1bn cancer hub in London

FDA starts swift review of Regeneron’s CD20 bispecific

Rare womb cancer is a women’s health success story

J&J doublet beats Tagrisso in first-line lung cancer

Novartis eyes first-line use of Lutathera after trial win

Seagen hails ‘practice-changing’ trial in bladder cancer

Lilly plans Q1 2027 filing for obesity triple retatrutide

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks